How to Optimize the Care Cascade of Hepatitis C Virus Infection

Kim, Beom Kyung

doi:10.5009/gnl220452

Cited by 3 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we found that only 51.3% of participants with HCV antibody-positive underwent HCV-RNA testing. This rate was higher than the national average level (18%) ( 2 ) , similar to studies conducted in the USA (50%) ( 4 ), but lower than rates in Brazil (67.7%) ( 5 ), the Republic of Korea (70%) ( 6 ), and the global goal (90%). Participants with low educational levels and poor awareness of HCV-related knowledge had a lower testing rate.…”

Section: Discussionsupporting

confidence: 77%

“…Our study discovered that only 1,179 (38.7%) individuals had received ART prior to entering the study, which falls well below the global elimination target of 80% for eligible individuals with positive HCV RNA. Previous evidence has also indicated low rates of HCV treatment uptake worldwide, with average rates of 1.3% in China (2), 34.1% in Brazil (5), and 28% in the U.S. (8). This study indicates that a higher level of education and greater awareness of HCV-related knowledge can enhance the ART uptake among individuals with HCV infection.…”

Section: Discussionmentioning

confidence: 48%

See 1 more Smart Citation

Diagnosis, Treatment, and Associated Factors Among Patients with HCV Infection — Jiangsu Province, China, 2004–2020

Yang,

Lu,

Zhang

et al. 2024

China CDC Weekly

View full text Add to dashboard Cite

What is already known on this topic? The global efforts to address the hepatitis C virus (HCV) are progressing, but there are still significant gaps in the diagnosis and treatment of HCV, leading to an increasing number of deaths related to HCV. What is added by this report? An extensive investigation was conducted to assess HCV RNA diagnosis, treatment uptake, and associated factors among individuals infected with HCV within Jiangsu Province. The study encompassed a large geographical area and utilized a substantial sample size. What are the implications for public health practice? Implementing focused interventions to improve the timely diagnosis of HCV RNA and increase the uptake of HCV treatment could effectively reduce the future burden of HCV-related health problems, deaths, and healthcare expenses. This is essential for achieving the global target of eliminating hepatitis C.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 48%

Diagnosis, Treatment, and Associated Factors Among Patients with HCV Infection — Jiangsu Province, China, 2004–2020

Yang,

Lu,

Zhang

et al. 2024

China CDC Weekly

View full text Add to dashboard Cite

show abstract

“…In addition, medical follow-ups by hepatologists were continued for non-treatable patients who decided to initiate DAA treatment according to the anticancer treatment response (n = 8) or were waiting for the approval of sofosbuvir/velpatasvir/voxilaprevir in South Korea (n = 2). Considering that the current KNHIS covers most DAAs with high SVR rates, requiring only short treatment periods of 8-12 weeks, 10,24 these patients have ample opportunity to receive appropriate treatment in the era of pan-genotypic DAA. These results suggest that an essential aspect of the HCV care cascade is the appropriate referral of patients to hepatologists.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, there is still a risk of developing HCC in patients who have already achieved SVR, especially in patients with advanced fibrosis and cirrhosis 23 . Therefore, appropriate referral to a gastroenterologist is necessary for patients who tested positive for anti‐HCV antibodies to enable proper evaluation, treatment, and follow‐up, which might improve their long‐term prognosis 10,24–26 . The results suggest that the appropriate time to engage the hepatologist is to confirm a positive anti‐HCV result and not a positive HCV RNA result.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center

Lee,

Kim

et al. 2024

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

Background and AimLack of awareness disturbs proper care for hepatitis C virus (HCV) infections in patients undergoing surgery. We investigated the status of HCV screening, confirmation, and treatment in patients who underwent surgery.MethodsPatients who underwent surgery at a tertiary academic center between 2019 and 2021 were eligible for this retrospective study.ResultsBetween 2019 and 2021, 96 894 patients (40 121 males; 41.4%) who underwent surgery under general anesthesia were recruited. The median age of the participants was 55.0 years. Of the 83 920 (86.6%) patients who tested positive for anti‐HCV antibodies, 576 (0.7%) showed positive results, with a higher proportion of patients with diabetes mellitus (32.6% vs 18.5%), hypertension (50.5% vs 28.6%), liver cirrhosis (13.2% vs 1.7%), and unfavorable laboratory test results when compared with those with negative results (all P < 0.05). HCV RNA was tested in 215 patients (37.3%), with a positivity rate of 20.5% (n = 44). Of the 44 patients, 42 (95.5%) were referred for antiviral treatment, and 29 (69.0%) were successfully treated with direct‐acting antiviral therapy. HCV RNA confirmation rates were higher in the Department of Hepatobiliary and Transplant Surgery (76.6%) than in the other surgical departments (25.0–33.5%) (P < 0.001).ConclusionsThe proportion of patients who were positive for anti‐HCV antibodies and failed to receive proper management after surgery was not negligible. Increased awareness of HCV infection among surgeons through appropriate education may be required.

show abstract

Improving the model of payment for medical care for chronic viral hepatitis C in the framework of the implementation of the Program of State Guarantees of Free Provision of Medical Care to Citizens for 2023 and for the planned period of 2024–2025

et al. 2023

View full text Add to dashboard Cite

Background. In 2021, new clinical guidelines for the treatment of chronic hepatitis C virus (HCV) in adults were published that did not contain interferon drug therapy regimens. Current therapy of chronic HCV is based on modern drugs of direct-acting antivirals (DAA). In this regard, the model of diagnosis-related groups (DRG) with the use of interferon-containing drugs as etiotropic therapy, which has been in effect until now, has lost its relevance and cannot be used to pay for cases of medical care for chronic HCV within the framework of the Program of State Guarantees of Free Medical Care to Citizens for 2023 and for the planning period of 2024–2025 (PSG). Objective: to improve the DRG model to pay for medical care for chronic HCV in a day hospital based on current clinical recommendations.Material and methods. Regulatory legal documents on the subject of the study, proposals and expert opinions of specialists, as well as feedback from public organizations, including patients, regarding the payment of medical care for chronic HCV, sent as part of a public discussion of the draft PSG, were studied. For the calculations were used: the current version of the clinical recommendations "Chronic viral hepatitis C"; impersonal personalized information of the database of registers of bills for payment for medical care for 2020–2021; the state register of manufacturers' maximum selling prices for medicines included in the list of vital and essential drugs.Results. A DRG model was developed to pay for medical care during drug therapy of chronic HCV, including for children. When calculating the model, the cost of medicines, patient days and the principles of accounting for the duration of hospitalization were updated.Conclusion. The developed DRG model to pay for medical care for chronic HCV in a day hospital with the use of drug therapy regimens with DAA recommended by clinical guidelines, including for children with HCV, contributes to improving the effectiveness of the system of payment for medical care provided as part of the implementation of the PSG and accessibility of medical care for this contingent of patients.

show abstract

How to Optimize the Care Cascade of Hepatitis C Virus Infection

Cited by 3 publications

References 10 publications

Diagnosis, Treatment, and Associated Factors Among Patients with HCV Infection — Jiangsu Province, China, 2004–2020

Diagnosis, Treatment, and Associated Factors Among Patients with HCV Infection — Jiangsu Province, China, 2004–2020

Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center

Improving the model of payment for medical care for chronic viral hepatitis C in the framework of the implementation of the Program of State Guarantees of Free Provision of Medical Care to Citizens for 2023 and for the planned period of 2024–2025

Contact Info

Product

Resources

About